References
- WHO COVID-19 dashboard [Internet]. 2024 [cited 2024 Jun 6]. Available from: https://covid19.who.int/
- Tian D, Sun Y, Zhou J, et al. The global epidemic of the SARS-CoV-2 delta variant, key spike mutations and immune escape. Front Immunol. 2021;12:751778. doi: 10.3389/fimmu.2021.751778
- Gupta RK, Topol EJ. COVID-19 vaccine breakthrough infections. Science. 2021;374(6575):1561–1562. doi: 10.1126/science.abl8487
- Li X. Omicron: Call for updated vaccines. J Med Virol. 2022;94(4):1261–1263. doi: 10.1002/jmv.27530
- Sheward DJ, Kim C, Fischbach J, et al. Omicron sublineage BA.2.75.2 exhibits extensive escape from neutralising antibodies. Lancet Infect Dis. 2022;22(11):1538–1540. doi: 10.1016/S1473-3099(22)00663-6
- Yoon JJ, Toots M, Lee S, et al. Orally efficacious broad-spectrum ribonucleoside analog inhibitor of influenza and respiratory syncytial viruses. Antimicrob Agents Chemother. 2018;62(8):e00766–18. doi: 10.1128/AAC.00766-18
- Product Assessment Report of Molnupiravir, European Medicines Agency, European Union. 2022 [cited 2022 Nov 1]. Available online https://www.google.com/url?sa=t&rct=j&q=&esrc=s&source=web&cd=&cad=rja&uact=8&ved=2ahUKEwj4lcP16rv5AhWchv0HHcLtDW0QFnoECAIQAQ&url=https%3A%2F%2Fwww.ema.europa.eu%2Fen%2Fdocuments%2Freferral%2Flagevrio-also-known-molnupiravir-mk-4482-covid-19-article-53-procedure-assessment-report_en.pdf&usg=AOvVaw3l1W4pGFCLhRRx3AAV3n7Q
- Drug label of LAGEVRIO-molnupiravir capsule, 10/2023 version, merck sharp & dohme LLC.
- Komarov T, Karnakova P, Archakova O, et al. Development and validation of a high-performance liquid chromatography with tandemmass spectrometry (HPLC-MS/MS) method for quantification ofmajor molnupiravir metabolite (β-D-N4-hydroxycytidine) in human plasma. Biomedicines. 2023;11(9):2356. doi: 10.3390/biomedicines11092356
- Fischer WA 2nd, Eron JJ, Holman W, et al. A phase 2a clinical trial of molnupiravir in patients with COVID-19 shows accelerated SARS-CoV-2 RNA clearance and elimination of infectious virus. Sci Transl Med. 2022;14(628):eabl7430. doi: 10.1126/scitranslmed.abl7430
- Painter WP, Holman W, Bush JA, et al. Human safety, tolerability, and pharmacokinetics of molnupiravir, a novel broad-spectrum oral antiviral agent with activity against SARS-CoV-2. Antimicrob Agents Chemother. 2021;65(5):e02428–20. doi: 10.1128/AAC.02428-20
- Nakamura K, Fujimoto K, Hasegawa C, et al. A phase I, randomized, placebo-controlled study of molnupiravir in healthy Japanese to support special approval in Japan to treat COVID-19. Clin Transl Sci. 2022;15(11):2697–2708. doi: 10.1111/cts.13395